

### **OHDSI Network Studies**

### OHDSI Community Call April 6, 2021 • 11 am ET



www.ohdsi.org





### **April/May OHDSI Community Calls**

Date	Торіс
April 6	OHDSI Network Studies
April 13	10-Minute Tutorials
April 20	Community Presentations (Theme: Local Impacts of OHDSI)
April 27	OHDSI Networking Session
May 3	Workgroup Updates
May 10	OHDSI Debates
May 17	Focus Topic: Prostate Cancer Study-A-Thon
May 24	OHDSI Fun







### March/April OHDSI Community Calls

Date	Topic			
April 6	OHDSI Network Studies			
April 13	10-Minute Tutorials			
April 20	Community Presentations (Theme: Local Impacts of OHDSI)			
April 27	OHDSI Networking Session			
May 3	Workgroup Updates			
May 10	OHDSI Debates			
May 17	Focus Topic: Prostate Cancer Study-A-Thon			
May 24	OHDSI Fun			







### **10-Minute Tutorials**



### **ATHENA/Vocabulary**

Mik Kallfelz



### USAGI

### **Maxim Moinat**



### PHOEBE

### **Anna Ostropolets**



### ACHILLES

### **Frank DeFalco**



www.ohdsi.org





### **Three Stages of The Journey**

# Where Have We Been? Where Are We Now? Where Are We Going?






www.ohdsi.org





Congratulations to the team of **Jimyung** Park, Seng Chan You, Eugene Jeong, Chunhua Weng, Dongsu Park, Jin Roh, Dong Yun Lee, Jae Youn Cheong, Jin Wook Choi, Mira Kang, and Rae Woong Park for this recent study in JMIR Informatics: A Framework (SOCRATex) for **Hierarchical Annotation of Unstructured Electronic Health Records and Integration Into a Standardized Medical Database: Development and Usability Study**.



Abstract	Abstract
Abstract	
<ul> <li>Introduction</li> </ul>	Background:
<ul> <li>Methods</li> </ul>	Although electronic health records (EHRs) have been widely used in secondary asses
<ul> <li>Results</li> </ul>	clinical documents are relatively less utilized owing to the lack of standardized clinical
Discussion	frameworks across different institutions.
<ul> <li>Abbreviations</li> </ul>	Objective:
Copyright	This study aimed to develop a framework for processing unstructured clinical docum and integration with standardized structured data.
	Methods:
	We developed a framework known as Staged Optimization of Curation, Regula
	Annotation of clinical text (SOCRATex). SOCRATex has the following four aspect

clinical notes for the target population and preprocessing the data, (2) defining t schema with a hierarchical structure, (3) performing document-level hierarchical a



#### #JoinTheJourney



ssments al text



Congratulations to the team of Hao Liu, Yuan Chi, Alex Butler, **Yingcheng Sun, and Chunhua** Weng for this study published in the Journal of Biomedical Informatics: A Knowledge Base of Clinical Trial Eligibility Criteria.



Journal of Biomedical Informatics Available online 1 April 2021, 103771 In Press, Journal Pre-proof (?)

#### Special Communication

A Knowledge Base of Clinical Trial Eligibility Criteria

Hao Liu<sup>1</sup>, Yuan Chi<sup>1</sup>, Alex Butler, Yingcheng Sun, Chunhua Weng 🙁 🖾

Show more 🗸

+ Add to Mendeley 😪 Share 🗦 Cite

https://doi.org/10.1016/j.jbi.2021.103771

Get rights and content

#### Highlights

- Eligibility criteria extracted from 352,110 clinical trials in Clinical Trials.gov.
- A unique large-scale knowledge base with computable eligibility criteria entities and attributes.
- User-friendly web interface to enable queries and visualization.
- Enable clinical trial cohort definition, population representativeness assessment, electronical phenotyping.







Congratulations to the team of **Clair Blacketer, Frank DeFalco, Patrick Ryan and Peter Rijnbeek** on this recent preprint posted to MedRxiv: Increasing Trust in **Real-World Evidence Through Evaluation of Observational Data Quality**. Community feedback is appreciated.







THE PREPRINT SERVER FOR HEALTH SCIENCES

O Comment on this paper

Increasing Trust in Real-World Evidence Through Evaluation of Observational Data Quality

Olair Blacketer, Frank J Defalco, Patrick B Ryan, Peter R Rijnbeek doi: https://doi.org/10.1101/2021.03.25.21254341

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Abstract Full Text Info/History Metrics Preview PDF

#### ABSTRACT

Advances in standardization of observational healthcare data have enabled methodological breakthroughs, rapid global collaboration, and generation of real-world evidence to improve patient outcomes. Standardizations in data structure, such as use of Common Data Models (CDM), need to be coupled with standardized approaches for data quality assessment. To ensure confidence in real-world evidence generated from the analysis of real-world dat on must first have confidence in the data itself. The Data Quality Dashboard is an ope package that reports potential quality issues in an OMOP CDM instance through the execution and summarization of over 3,300 configurable data quality checks. We design that the pate of the data for the d







### **CDM Brainstorm Session March 30**

### Thank you to everybody who took part in last week's 2-hour CDM 5.4 Brainstorm Session!

# Any updates from the meeting?

#### KR1: List of Changes

Tuesday, March 16, 2021 10:25 AM

#### Start with v5.3 -> v5.4?

#### **Easy Additions**

- PROCEDURE\_OCCURRENCE
  - PROCEDURE\_STATUS\_CONCEPT\_ID
     Similar to CONDITION\_STATUS\_CONCEPT\_ID #376 maybe
- Similar to CONDITION\_STATU
   LOCATION CONCEPT ID
  - Make the location table international <u>#365</u>
  - Do we also need REGION\_CONCEPT\_ID and COUNTRY\_CONCEPT\_ID or is that subsumed by LOCATION\_CONCEPT\_ID?
- UDI field in DEVICE\_EXPOSURE
  - Make 250 characters to allow all permutations of UDI technically just a DDL change
- UNIT\_CONCEPT\_ID in DEVICE\_EXPOSURE #264
- UNIT\_SOURCE\_CONCEPT\_ID in MEASUREMENT #259
- Representation of infusion rates is this solved with DOSE\_UNIT\_SOURCE\_VALUE? #224
- Add METADATA\_ID and VALUE\_AS\_NUMBER to METADATA #202
- Add VALUE\_SOURCE\_VALUE to OBSERVATION #193
- Change CDM\_VERSION in CDM\_SOURCE to numeric and use a concept\_id <u>#306</u>
   Also \*technically\* breaking but really a DDL change
- Add DEATH\_DATE alongside the DEATH table?
  - Add DEATH\_TYPE\_CONCEPT\_ID to PERSON
- EPISODE and EPISODE\_EVENT

#### Potentials

- Rename VISIT\_DETAIL\_PARENT\_ID to PARENT\_VISIT\_DETAIL\_ID #329
  - This is \*technically\* breaking but I don't believe any standard processes currently reference it
- GENDER\_CONCEPT\_ID
  - Changing this to SEX\_CONCEPT\_ID would be a breaking change. Should we add it instead and keep both fields?
- PROCEDURE\_END\_DATETIME #286
  - Agree, convention that if no end\_datetime then set to start\_datetime
  - This would necessitate the addition of procedure\_start\_datetime or renaming of procedure\_date
  - $\circ$   $\;$  Instead, add length of procedure to get around the breaking change

#### MBLACKE@ITS.JNJ.COM









### **OHDSI Newsletter**



#### **OHDSI**

#### The Journey Newsletter (April 2021)

The OHDSI community collaborated in efforts around vaccine surveillance, prostate cancer research and a data visualization challenge, while publishing more than 10 studies in either medical journals or a preprint server. Check out all the details and more in the latest OHDSI Newsletter. #JoinTheJourney



#### Where Have We Been?

• The OHDSI community published several studies in both top medical journals and preprint servers, including studies on <u>COVID-19 patients with autoimmune</u> <u>disorders</u> (Rheumatology), <u>Effectiveness and Safety of First-Line β-Blocker</u> <u>Monotherapy in Hypertensive Patients</u> (Hypertension), <u>The Incidence of</u> <u>Adverse Events of Special Interest for COVID-19 Vaccines</u> (MedRxiv) and the <u>CHARYBDIS Project</u> (Research Square). A full list of studies from the last month is posted below.

# OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

Who We Are 🗸 OHDSI Updates & News 🗸 Standards Software Tools OHDSI Studies Book of OHDSI 🗸 Resources 🗸 New To OHDSI?

EHDEN Academy v This Week In OHDSI v Events & Collaborations v Collaborate with OHDSI in MSTearls v Social Media/Newsletter v

#### Welcome to OHDSI!

The Observational Health Data Sciences and Informatics (or OHDSI, pronounced "Odyssey") program is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics. All our solutions are open-source.

OHDSI has established an international network of researchers and observational health databases with a central coordinating center housed at Columbia University.

Read more about us, about our goals, and how

2020 OHDSI ON LinkedIn OHDSI ON YouTube

the link below.

Our 2020 OHDSI Global Symposium brought together a global research community for 18 hours of open science, international collaboration and community fun. The day included research presentations from community members, panels that brought together leaders from major healthcare organizations, as well as network sessions, the annual collaborator showcase, and plenty more. Check it all out at

Newsletter

OHDSI on Twitter

2020 OHDSI Global Symposium

### 💟 @OHDSI

#### www.ohdsi.org

#### #JoinTheJourney



> Subscribe

April 2021

March 2021

June 2020

February 2020

February 2021 October 2020





### Any shoutouts from the community? Please share and help promote and celebrate OHDSI work!



Have a study published? Please send to <u>sachson@ohdsi.org</u> so we can share during this call and on our social channels. Let's work together to promote the collaborative work happening in OHDSI!




www.ohdsi.org



### **Three Stages of The Journey**

# Where Have We Been? Where Are We Now? Where Are We Going?





www.ohdsi.org





### **Upcoming Workgroup Calls**



Date	Time (ET)	Meeting			
Tuesday 1 pm		Common Data Model			
Tuesday 3 pm		OMOP CDM Oncology – Outreach/Research Subgroup			
Wednesday	2 am	Patient-Level Prediction/Population-Level Estimation (Eastern)			
Thursday	1 pm	OMOP CDM Oncology – CDM/Vocabulary Subgroup			
Friday	10 am	China Chapter			
Friday	1 pm	Phenotype Development and Evaluation			

www.ohdsi.org/upcoming-working-group-calls







### Next APAC Community Call

The next APAC Community Call will be this Wednesday/ Thursday, and will focus on OHDSI APAC OMOP Projects. Presenters will be Yuan Lu and Namki Hong. Calls are hosted within the OHDSI APAC Team environment.

### **TOPICS**

Yuan Lu: Comprehensive comparative effectiveness and safety of secondline antihypertensive agents: Utilizing the LEGEND principles to mobilize collaboration across the OHDSI APAC network

## Namki Hong: Development of Common Data Model for Rare Endocrine Diseases (REDCDM) platform







### **Next APAC Community Call**

Our new OHDSI APAC web page (ohdsi.org/apac) is now live and will host the recordings of previous OHDSI APAC calls, as well as more information from the regional chapters.

#### **OHDSI APAC - Our Asia-Pacific Community**

OHDSI is a global, multi-stakeholder, interdisciplinary and openscience network that collaborates to bring out the value of health data through large-scale analytics. Our Asia-Pacific (APAC) community comprises six regional chapters (Australia, China, Japan, Singapore, South Korea, Taiwan) and has led important OHDSI initiatives around the world.

The first OHDSI APAC Symposium was held virtually Dec. 5-6, 2020, and it provided an opportunity for our Asia-Pacific collaborators (along with others around the world) to share research, provide community updates, collaborate in regional breakouts or network discussions, and have some OHDSI fun.



Upcoming APAC Community Calls

The APAC community has its own group in the OHDSI MS Teams environment to promote greater collaboration on our collaborative efforts. It will also be the home of our bi-weekly APAC Community Calls, where we will provide updates, share research presentations, collaborate on topics of shared interest, and plenty more. How can you get involved? First, <u>reguest access to our MS Teams Environment</u>, then request access to <u>our OHDSI APAC workgroup</u>. You can also join the meetings <u>by using this direct link</u>.

Our calls, which are scheduled on a bi-weekly basis, take place Thursday at 10 am CST/SGT, 11 am KST/JST, 12:30 pm ACDT, as well as Wednesday at 10 pm EST and 7 pm PST.

 Mar. 11, 2021 - Collaborator Showcase (Presentations by Ty Stanford and Jason Hsu) All calls are recorded, so if you miss one or want to share with a collaborator, Theme - Collaborator Showcas + Mar. 25, 2021 - OHDSI APAC Network Research (Presentations by Yu Meeting contents included the following OHDSI presentations - Mar. 11, 2021 - Collaborator Showcase (Presentations by Ty Stanfo Ty Stanford – Mapping to standardized vocabularies: a process for medicine codes in Australia · Jason Hsu and Alex Aguyen - Introduction of Taipei Medical University Clinical Research Database; TMUCDR - OHDSI CDM Mapping Progress Slides Stanford | Hsu/Aguyen Recordinas Ty Stanford BACKGROUND Conversion of your clinical data to the OMOP common data model (CDM) has two main steps: 1. Convert your data source into the CDM pre-specified tables 2. Convert native vocabulari

('source' codes) to be tran their respective OHDSI

'standardized vocabularies



#### #JoinTheJourney



Note\_NLP



### 2021 OHDSI Symposium







The 2021 OHDSI Symposium will be held Sept. 12-15.

More details will be announced when available, but please save those dates for the highlight event of the OHDSI year! #JoinTheJourney







### **CBER Best Initiative Seminar Series**

The next edition of the CBER Best Initiative Seminar Series will be held Wednesday, May 5, at 11 am ET. **Dr. Ben Goldstein** will discuss "Understanding Informed Presence in Electronic Health Records Data" during that session.

Registration is free, and everybody is invited. You can register at:

https://northeastern.zoom.us/webinar/register/WN\_UkPMnpakQ4 qRMJS7O459pA

#### **CBER BEST Initiative Seminar Series**



Date: May 5, 2021

Time: 11:00 -12:00 PM EDT

Topic:

Understanding Informed Presence in Electronic Health Records Data

#### Background:

The <u>GBER BEST Initiative</u> Seminar Series is designed to share and discuss recent research of relevance to ongoing and future surveillance activities of CBER regulated products, namely biologies. The series focuses on safety and effectiveness of biologies including vaccines, blood components, blood-derived products, tissues and advanced therapies. The seminars will provide information on characteristics of biologies, required infrastructure, study designs, and analytic methods utilized for pharmacovigilance and pharmacoepidemiologic studies of biologies. They will also cover information regarding potential data sources, informatics challenges and requirements, utilization of real-world data and evidence, and risk-benefit analysis for biologie products. The length of each session may vary, and the presenters will be invited from outside FDA. Please see the details below for our upcoming seminar. <u>Anyone can register and join for free</u>. Stay tuned for more details and additional webinars during the course of the year.

**Description:** Electronic Health Records (EHR) data have become a key data source for clinical research. Their relative availability and abundance make them very appealing for analytic tasks ranging from comparative effectiveness research, disease surveillance, population health, and predictive modeling. However, as has been widely documented, as a real-world data source, there are a number of analytic challenges with EHR data. One of the key challenges of EHR data relates to the observability of the underlying data. While fundamentally a missing data problem, we have termed this process *informed presence* to highlight that what we observe is informative. In this talk I will provide some illustrations for how informed presence can bias insights and inference with EHR data are an extremely useful data source, though like any complicated data source need to be used thoughtfully.

Presenter: Dr. Ben Goldstein, PhD, MPH



Benjamin Goldstein is Associate Professor of Biostatistics and Bioinformatics at Duke University. He is a member of the Duke Clinical Research Institute and serves as the Science Lead for the Children's Health Discovery Initiative. Dr. Goldstein's research focuses on the meaningful use of electronic health records data. His work sits at the intersection of biostatistics, biomedical informatics, machine learning and epidemiology. He works closely with the Duke University Health System developing, implementing and evaluating risk prediction and clinical decision support tools. He also studies how patients' informative visit process can impact inference in EHR based studies. Dr. Goldstein received his PhD in Biostatistics and MPH in Biostatistics and Epidemiology from UC Berkeley.

Registration: https://northeastern.zoom.us/webinar/register/WN\_UkPMnpakQ4qRMJS7O459pA







### Where Are We Going?

Any other announcements of upcoming work, events, deadlines, etc?






www.ohdsi.org





### **Three Stages of The Journey**

# Where Have We Been? Where Are We Now? Where Are We Going?





www.ohdsi.org







Cancer Risk Between H2 Blockers

**Seng Chan You** 



MSKAI- Musculoskeletal adverse events following hormonal treatment for breast cancer: Cohort Diagnostics to establish feasibility Jenny Lane



Covid-19 pandEmic impacts on mental health Related conditions Via multidatabase nEtwork: a LongitutinaL Observational study (CERVELLO) Carmen Olga-Torre



Alpha-1 blocker for Palliating Inflammatory injury Severity (APIS) study

### **Aki Nishimura**



Calculating the background rates of adverse events of special interest (AESI) for the COVID vaccines

### **Xintong Li**



**Evaluating Use of Methods for Adverse Event Under Surveillance (EUMAEUS)** 

### Martijn Schuemie







 Who We Are 
 OHDSI Updates & News 
 Standards
 Software Tools
 OHDSI Studies
 Eook of OHDSI 
 Resources 
 New To OHDSI? 

EHDEN Academy v This Week In OHDSI v Events & Collaborations v slaborate with OHDSI in MSTeams v Social Media/Newsletter v

#### Welcome to IDSI!

The Observational path Data Sciences and Informatics (or OHDSI, pronounced "Odyssey") program is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics. All our solutions are open-source.

OHDSI has established an international network of researchers and observational health databases with a central coordinating center housed at Columbia University.

#### 2020 OHDSI Symposium

Our 2020 OHDSI Global Symposium brought together a global research community for 18 hours of open science, international collaboration and community fun. The day included research presentations from community members, panels that brought together leaders from major healthcare organizations, as well as network sessions, the annual collaborator showcase, and plenty more. Check it all out at the link below.

2020 OHDSI Global Symposium

### 💟 @OHDSI

#### www.ohdsi.org





#### OHDSI Studies

OHDSI is a global, open-science community that is committed to generating real-world evidence to both support clinical decision-making and advance the methodology within this field. We have collaborated on many network studies across our community, many of which (both past and ongoing) are listed in this table. Please click on any listing that interests you to learn more about the study, and how you can potentially collaborate to generate reliable, reproducible evidence.

All       A	All
Covid-19 pandEmic impacts on mental health Related       Characterization       Clinical Application       psychiatryWG, mental-health, C       Started       Carmen Olga Torre, Hao Luo         Evaluating Use of Methods for Adverse Event Under       Population-Level Estimation       Methods Research       Design Finalized       Martijn Schuemie       2021-07         MSKAI- Musculoskeletal adverse events following ho       Characterization & Population       Clinical Application       OHDSI       Started       Jenny Lane       2021-07         Calculating the background rates of adverse events       Characterization & Population       Clinical Application       OHDSI       Started       Jenny Lane       2021-07         Evaluating the Sensitivity Of Prediction Model Dev       Patient-Level Prediction       Methods Research, Clinical Application       COVID-19       Design Finalized       Jenna Reps       Evaluating the Sensitivity Of Prediction Model Dev       Foharacterization       Clinical Application       cancer       Started       Jenna Reps       Evaluating the Sensitivity Of Prediction Model Dev       Foharacterization       Clinical Application       cancer       Started       Giorgio Gandaglia       Evaluating the Sensitivity Of Prediction Model Dev       Foharacterization       Clinical Application       cancer       Started       Giorgio Gandaglia       Evaluating the Sensitivity Of Prediction Sensearch Clinical Application	
Evaluating Use of Methods for Adverse Event Under       Population-Level Estimation       Methods Research       Design Finalized       Martijn Schuemie       2021-00         MSKAI- Musculoskeletal adverse events following hom       Characterization & Population       Clinical Application       OHDSI       Started       Jenny Lane       Evaluating the background rates of adverse events       Characterization & Population       Clinical Application       COVID-19       Design Finalized       George Hripcsak, Patrick Ryan,       Evaluating the Sensitivity Of Prediction Model Dev       Patient-Level Prediction       Methods Research, Clinical App       COVID-19       Started       Jenna Reps       Evaluating the Sensitivity Of Prediction Model Dev       Characterization       Clinical Application       cancer       Started       Giorgio Gandaglia       Evaluating the Sensitivity Of Prediction Model Dev       Characterization       Clinical Application       cancer       Started       Giorgio Gandaglia       Evaluating the Sensitivity Of Prediction Sense       Giorgio Gandaglia       Evaluating the Sense       Giorgio Gandaglia       Evaluating the Sense       Started       Giorgio Gandaglia       Evaluating the Sense       Gi	2021-04-06
MSKAI- Musculoskeletal adverse events following ho       Characterization & Population       Clinical Application       OHDSI       Started       Jenny Lane         Calculating the background rates of adverse events       Characterization       Clinical Application       COVID-19       Design Finalized       George Hripcsak, Patrick Ryan,         Evaluating the Sensitivity Of Prediction Model Dev       Patient-Level Prediction       Methods Research, Clinical App       COVID-19       Started       Jenna Reps         Long term outcomes of prostate cancer patients und       Characterization       Clinical Application       cancer       Started       Giorgio Gandaglia         PROTEUS Cohort Diagnostics RCRI study       Characterization       Clinical Application       PROTEUS, Study-a-thon       Repo Created       Gowtham Rao       2020-10	2021-04-00
Calculating the background rates of adverse events       Characterization       Clinical Application       COVID-19       Design Finalized       George Hripcsak, Patrick Ryan,         Evaluating the Sensitivity Of Prediction Model Dev       Patient-Level Prediction       Methods Research, Clinical App       COVID-19       Started       Jenna Reps         Long term outcomes of prostate cancer patients und       Characterization       Clinical Application       cancer       Started       Giorgio Gandaglia         PROTEUS Cohort Diagnostics RCRI study       Characterization       Clinical Application       PROTEUS, Study-a-thon       Repo Created       Gowtham Rao       2020-10	1-12 2021-04-06
Evaluating the Sensitivity Of Prediction Model DevPatient-Level PredictionMethods Research, Clinical AppCOVID-19StartedJenna RepsLong term outcomes of prostate cancer patients undCharacterizationClinical ApplicationcancerStartedGiorgio GandagliaPROTEUS Cohort Diagnostics RCRI studyCharacterizationClinical ApplicationPROTEUS, Study-a-thonRepo CreatedGowtham Rao2020-10	2021-04-03
Long term outcomes of prostate cancer patients undCharacterizationClinical ApplicationcancerStartedGiorgio GandagliaPROTEUS Cohort Diagnostics RCRI studyCharacterizationClinical ApplicationPROTEUS, Study-a-thonRepo CreatedGowtham Rao2020-10	2021-04-02
PROTEUS Cohort Diagnostics RCRI study Characterization Clinical Application PROTEUS, Study-a-thon Repo Created Gowtham Rao 2020-10	2021-04-02
	2021-04-02
Characterizing Health Associated Risks, and Your B Characterization Clinical Application OHDSI, Study-a-thon, COVID-19 Results Available Talita Duarte-Salles, Kristin 2020-04	0-21 2021-04-02
	4-21 2021-03-31
OHDSI COVID-19 Studyathon: Alpha-1 blocker for Pal Population-Level Estimation Clinical Application Study-a-thon, COVID-19 Design Finalized Aki Nishimura, Daniel Prieto A	2021-03-28
Phenotype Library Diagnostics Characterization Clinical Application Results Available Gowtham Rao 2020-10	0-08 2021-03-15
RCRI model validation study Patient-Level Prediction Clinical Application OHDSI 2020 Study-a-thon Results Available Jenna Reps, Peter Rijnbeek	2021-03-15
Evaluating Use of Methods for Vaccine Effectivenes       Population-Level Estimation       Methods Research       Started       Marc Suchard       2021-02	2-19 2021-03-10
Pooled cohort equation model validation study Patient-Level Prediction Clinical Application OHDSI 2020 Study-a-thon Design Finalized Jenna Reps, Peter Rijnbeek	2021-03-09
Project Sc(y)lla Estimation: SARS-Cov-2 Large-scal Population-Level Estimation Clinical Application OHDSI, Study-a-thon, COVID-19 Design Finalized George Hripcsak, Daniel Prieto	2021-03-08
Cancer Risk between H2 blockers Population-Level Estimation Clinical Application OHDSI-Korea, FEEDER-NET Design Finalized Seng Chan You, Seung In Seo, C 2020-01	1-31 2021-03-03
OHDSI Comparative effectiveness and safety of dire Population-Level Estimation Clinical Application OHDSI, DOAC, AF Complete Wallis CY Lau;	2021-02-22
Rheumatoid arthritis (RA) Drug Utilization 2020 (E Characterization Clinical Application Rheumatoid arthritis, Drug Uti Started Anthony G. Sena 2020-01	1-12 2021-02-19
Alcoholic Liver Disease (ALD): Medication and clin Characterization, Population-L Clinical Application Liver, Alcoholic liver disease Started Prof. Dr. Dr. Andreas Teufel,	2021-02-10
Comparative effectiveness and safety of anticoagul Population-Level Estimation Clinical Application OHDSI Started Seng Chan You, Makoto Mori, Ha	2021-01-15
Prediction Covariate Lookback Patient-Level Prediction Methods Research Repo Created Jill Hardin	
Incidence of COVID-19 and complication of COVID-19 Population-Level Estimation Clinical Application OHDSI-Korea, COVID-19 Design Finalized Jimyung Park, Seung In Seo	2021-01-13



#### www.ohdsi.org





Covid-19 pandEmic impacts on mental health Related	Characterization	Clinical Application	psychiatryWG, mental-health, C	Started	Carmen Olga Torre, Hao Luo		2021-04-06
Evaluating Use of Methods for Adverse Event Under	Population-Level Estimation	Methods Research		Design Finalized	Martijn Schuemie	2021-01-12	2021-04-06
MSKAI- Musculoskeletal adverse events following ho	Characterization & Population	Clinical Application	OHDSI	Started	Jenny Lane		2021-04-03
Calculating the background rates of adverse events	Characterization	Clinical Application	COVID-19	Design Finalized	George Hripcsak, Patrick Ryan,		2021-04-02
Evaluating the Sensitivity Of Prediction Model Dev	Patient-Level Prediction	Methods Research, Clinical App	COVID-19	Started	Jenna Reps		2021-04-02
Long term outcomes of prostate cancer patients und	Characterization	Clinical Application	cancer	Started	Giorgio Gandaglia		2021-04-02
PROTEUS Cohort Diagnostics RCRI study	Characterization	Clinical Application	PROTEUS, Study-a-thon	Repo Created	Gowtham Rao	2020-10-21	2021-04-02
Characterizing Health Associated Risks, and Your B	Characterization	Clinical Application	OHDSI, Study-a-thon, COVID-19	Results Available	Talita Duarte-Salles, Kristin	2020-04-21	2021-03-31
OHDSI COVID-19 Studyathon: Alpha-1 blocker for Pal	Population-Level Estimation	Clinical Application	Study-a-thon, COVID-19	Design Finalized	Aki Nishimura, Daniel Prieto A		2021-03-28
Phenotype Library Diagnostics	Characterization	Clinical Application		Results Available	Gowtham Rao	2020-10-08	2021-03-15
RCRI model validation study	Patient-Level Prediction	Clinical Application	OHDSI 2020 Study-a-thon	Results Available	Jenna Reps, Peter Rijnbeek		2021-03-15
Evaluating Use of Methods for Vaccine Effectivenes	Population-Level Estimation	Methods Research		Started	Marc Suchard	2021-02-19	2021-03-10
Pooled cohort equation model validation study	Patient-Level Prediction	Clinical Application	OHDSI 2020 Study-a-thon	Design Finalized	Jenna Reps, Peter Rijnbeek		2021-03-09
Project Sc(y)lla Estimation: SARS-Cov-2 Large-scal	Population-Level Estimation	Clinical Application	OHDSI, Study-a-thon, COVID-19	Design Finalized	George Hripcsak, Daniel Prieto		2021-03-08
Cancer Risk between H2 blockers	Population-Level Estimation	Clinical Application	OHDSI-Korea, FEEDER-NET	Design Finalized	Seng Chan You, Seung In Seo, C	2020-01-31	2021-03-03

Showing 1 to 15 of 63 entries

Previous 1 2 3 4 5 Next

### Covid-19 pandEmic impacts on mental health Related conditions Via multi-database nEtwork: a LongitutinaL Observational study (CERVELLO)

The primary objective of this study is to describe the baseline demographic, clinical characteristics, treatments and outcomes of interest among individuals with mental health conditions during the COVID-19 pandemic overall and stratified by sex, age, race and specific comorbidities.

Github repository	ohdsi-studies/Cervello
Study status	Started
Analytics use case(s)	Characterization
Study type	Clinical Application
Tags	psychiatryWG, mental-health, COVID-19
Study lead(s)	Carmen Olga Torre, Hao Luo
Study lead forums tag(s)	CarmenOT haoluo429
Study start date	
Last change date	April 06, 2021
Study end date	
Protocol	Word Doc
Publications	
Resuls explorer	https://data.ohdsi.org/cervelloDiagnostics/



www.ohdsi.org





PROTEUS Cohort Diagnostics RCRI study	Characterization	Clinical Application	PROTEUS, Study-a-thon	Repo Created	Gowtham Rao	2020-10-21	2021-04-02
Characterizing Health Associated Risks, and Your B	Characterization	Clinical Application	OHDSI, Study-a-thon, COVID-19	Results Available	Talita Duarte-Salles, Kristin	2020-04-21	2021-03-31
OHDSI COVID-19 Studyathon: Alpha-1 blocker for Pal	Population-Level Estimation	Clinical Application	Study-a-thon, COVID-19	Design Finalized	Aki Nishimura, Daniel Prieto A		2021-03-28
Phenotype Library Diagnostics	Characterization	Clinical Application		Results Available	Gowtham Rao	2020-10-08	2021-03-15
RCRI model validation study	Patient-Level Prediction	Clinical Application	OHDSI 2020 Study-a-thon	Results Available	Jenna Reps, Peter Rijnbeek		2021-03-15
Evaluating Use of Methods for Vaccine Effectivenes	Population-Level Estimation	Methods Research		Started	Marc Suchard	2021-02-19	2021-03-10
Pooled cohort equation model validation study	Patient-Level Prediction	Clinical Application	OHDSI 2020 Study-a-thon	Design Finalized	Jenna Reps, Peter Rijnbeek		2021-03-09
Project Sc(y)lla Estimation: SARS-Cov-2 Large-scal	Population-Level Estimation	Clinical Application	OHDSI, Study-a-thon, COVID-19	Design Finalized	George Hripcsak, Daniel Prieto		2021-03-08
Cancer Risk between H2 blockers	Population-Level Estimation	Clinical Application	OHDSI-Korea, FEEDER-NET	Design Finalized	Seng Chan You, Seung In Seo, C	2020-01-31	2021-03-03

Showing 1 to 15 of 63 entries

Previous 1 2 3 4 5 Next

#### Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2 (CHARYBDIS)

#### **Objectives:**

1) Describe the baseline demographic, clinical characteristics, treatments and outcomes of interest among individuals tested for SARS-CoV-2 and/or diagnosed with COVID-19 overall and stratified by sex, age, race and specific comorbidities;

2) Describe characteristics and outcomes of patients diagnosed/tested positive for influenza as well as patients hospitalized with influenza between September 2017 and April 2018 compared to the COVID-19 population.

Github repository	ohdsi-studies/Covid19CharacterizationCharybdis
Study status	Results Available
Analytics use case(s)	Characterization
Study type	Clinical Application
Tags	OHDSI, Study-a-thon, COVID-19
Study lead(s)	Talita Duarte-Salles, Kristin Kostka, Albert Prats-Uribe
Study lead forums tag(s)	tduarte, krfeeney, Albert_Prats
Study start date	April 21, 2020
Last change date	March 31, 2021
Study end date	
Protocol	Word Doc
Publications	
	- Shiny App: Cohort Diagnostics - COVID Targets
	- Shiny App: Cohort Diagnostics - Influenza Targets
Resuls explorer	- Shiny App: Cohort Diagnostics - Stratum
	- Shiny App: Cohort Diagnostics - Features
	- Shiny App: Characterization Study

Last updated: 2021-04-06 13:55:39 (Updated every 24 hours)



www.ohdsi.org







Cancer Risk Between H2 Blockers

**Seng Chan You** 



MSKAI- Musculoskeletal adverse events following hormonal treatment for breast cancer: Cohort Diagnostics to establish feasibility Jenny Lane



Covid-19 pandEmic impacts on mental health Related conditions Via multidatabase nEtwork: a LongitutinaL Observational study (CERVELLO) Carmen Olga-Torre



Alpha-1 blocker for Palliating Inflammatory injury Severity (APIS) study

### **Aki Nishimura**



Calculating the background rates of adverse events of special interest (AESI) for the COVID vaccines

### **Xintong Li**



**Evaluating Use of Methods for Adverse Event Under Surveillance (EUMAEUS)** 

### Martijn Schuemie

